Floatz logo

Rivoceranib

HRD-Positive/HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

224 Active assets in the HRD-Positive/HER2-Negative Advanced Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB

View all 50 →

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →